Medpace Holdings, Inc. (MEDP) |
| 611.57 -7.48 (-1.21%) 08-27 16:00 |
| Open: | 611.08 |
| High: | 624.99 |
| Low: | 610.625 |
| Volume: | 198,148 |
| Market Cap: | 17,070(M) |
| PE Ratio: | 35.85 |
| Exchange: | NASDAQ Global Select |
| Industry: | Medical - Diagnostics & Research |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 735.48 |
| Resistance 1: | 629.69 |
| Pivot price: | 603.32 |
| Support 1: | 588.75 |
| Support 2: | 563.45 |
| 52w High: | 677.9 |
| 52w Low: | 373 |
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
| EPS | 17.010 |
| Book Value | 15.550 |
| PEG Ratio | 3.32 |
| Gross Profit | 72.017 |
| Profit Margin (%) | 17.67 |
| Operating Margin (%) | 20.76 |
| Return on Assets (ttm) | 20.1 |
| Return on Equity (ttm) | 162.1 |
Thu, 27 Aug 2026
Medpace (MEDP) CEO sells 4,673 shares near $620 in open-market trades - Stock Titan
Wed, 26 Aug 2026
Medpace (NASDAQ: MEDP) director plans 3,858-share sale after option exercise - Stock Titan
Wed, 26 Aug 2026
If You Invested $1000 In Medpace Holdings Stock 10 Years Ago, You Would Have This Much Today - Benzinga
Wed, 26 Aug 2026
What Investors Should Know About Medpace CEO Troendle Selling $10 Million in Stock - The Globe and Mail
Wed, 26 Aug 2026
Medpace CEO Sells 15,978 Shares for $10 Million - Intellectia AI
Tue, 25 Aug 2026
Bronstein, Gewirtz & Grossman, LLC Is Investigating Medpace Holdings, Inc. (MEDP) And Encourages Stockholders to Connect - ACCESS Newswire
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |